- February 25, 2021Source: The New York Times
Nursing Homes, Once Hotspots, Far Outpace U.S. in Covid Declines
- February 23, 2021Source: Vox
The growing evidence that the Covid-19 vaccines can reduce transmission, explained
- February 23, 2021Source: WNPR
LISTEN: Yale Expert Says Vaccine Rollout Change 'Not Good Enough'
- February 22, 2021Source: Yale Daily News
Efficacy vs. efficiency: Which is the most important when it comes to COVID-19 vaccines?
- February 22, 2021Source: Rolling Stone
New Covid-19 Strains: What We Know
- February 22, 2021Source: News 8 wtnh.com
Johns Hopkins physician says U.S. could reach COVID herd immunity by April; officials urge continued caution
- February 22, 2021Source: News 8 wtnh.com
Experts discuss latest COVID-19 headlines; health issues while recovering from coronavirus
- February 19, 2021Source: Yale Daily News
Yale IMPACT team compiles biorepository of COVID-19 patient samples for study
Research in Epidemiology of Microbial Diseases
Infectious diseases are one of the main contributors to global mortality and morbidity. The Department of Epidemiology of Microbial Diseases (EMD) has a tradition of both research designed to understand the distribution, transmission, pathogenesis, and ultimately the control of pathogens. Areas of excellence include HIV/AIDS, vector biology, parasitology, molecular epidemiology, immunology, and the modeling of infectious diseases.
Laboratory Science
EMD has long tradition of public health discovery through laboratory science. In our first century, YSPH was home to the groups like the bacteriology lab, the Poliomyelitis Study Unit, the Arbovirus Research Unit which moved from the Rockefeller Foundation to Yale in 1964, and the WHO Serum bank. Scientists like Nobel prize winning Max Theiler have driven the field’s understanding of disease through basic science for generations, with major insights to both infectious and chronic diseases. Today, Yale is home to several laboratories addressing vector borne diseases transmitted by tsetse flies, sand flies, ticks, mosquitoes and more. In addition, there are robust groups of scientists pursuing solutions to respiratory ailments, antibiotic resistance, diagnostic testing, vaccine development and infections related to STIs and intravenous drug use.
Practice-based research and initiatives
YSPH scientists are on the front lines of response with local health ministers to identify and address issues arising from recent outbreaks of 2019-nCoV, Zika and Ebola, as well as leptospirosis and other neglected tropical diseases. YSPH, in collaboration with the State of Connecticut Department of Public Health, is also home to one of the CDC’s 10 Emerging Infection Programs.
